Israel may drop planned HPV vaccination program

Israeli health ministry officials are reportedly considering dropping plans to give HPV vaccines to 52,000 teenage girls. The hesitancy comes after Israeli scientists were involved with two papers linking the vaccines to autoimmune conditions and other adverse events. News (sub. req.)

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.